Trial Profile
A Phase 1, First-In-Human, Dose-Seeking Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs ABT 301 (Primary)
- Indications Carcinoma; Ductal carcinoma; Endometrial cancer; Liver cancer; Malignant thymoma; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 09 Apr 2019 Status changed from recruiting to completed.
- 12 Sep 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.